Bokf Na Has $1.11 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Bokf Na lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 17.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,213 shares of the medical research company’s stock after buying an additional 3,875 shares during the period. Bokf Na’s holdings in Exact Sciences were worth $1,108,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of EXAS. Benjamin F. Edwards & Company Inc. boosted its position in shares of Exact Sciences by 65.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after buying an additional 179 shares during the period. Able Wealth Management LLC acquired a new stake in shares of Exact Sciences in the fourth quarter worth $45,000. EverSource Wealth Advisors LLC boosted its position in shares of Exact Sciences by 92.4% in the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Exact Sciences in the first quarter worth $55,000. Finally, GAMMA Investing LLC boosted its position in shares of Exact Sciences by 48.4% in the second quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after buying an additional 444 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

EXAS has been the subject of several recent research reports. Wells Fargo & Company initiated coverage on Exact Sciences in a report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 price objective for the company. Scotiabank initiated coverage on Exact Sciences in a report on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price objective for the company. Stifel Nicolaus cut their price objective on Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Piper Sandler raised their target price on Exact Sciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $75.00 target price on shares of Exact Sciences in a report on Friday. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.14.

Exact Sciences Trading Down 2.7 %

EXAS stock opened at $65.54 on Monday. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The firm has a market cap of $12.11 billion, a P/E ratio of -49.65 and a beta of 1.26. The business’s 50 day moving average is $54.89 and its 200-day moving average is $55.44. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company had revenue of $699.26 million for the quarter, compared to analyst estimates of $690.02 million. During the same period in the prior year, the company posted ($0.45) EPS. The company’s revenue was up 12.4% compared to the same quarter last year. Equities analysts anticipate that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.